Literature DB >> 12042115

An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids.

Armin Madadkar Sobhani1, Sultan-Ahmad Ebrahimi, Massoud Mahmoudian.   

Abstract

PURPOSE: Peganum harmala L. (Zygophyllaceae) seeds extract is one of the main components of an ethnobotanical preparation used in the treatment of neoplasms in Iran. Cytotoxic effects of P. harmala extract on cancerous cell-lines have been reported before. beta-carbolines like harmaline and harmine are the major alkaloids present in the seeds of the P. harmala. Considering reports concerning DNA topoisomerase inhibition by other beta-carbolines like harmane, we have used DNA relaxation assays to investigate topoisomerase I inhibitory activity of P. harmala seeds extract and its beta-carboline alkaloids to further inspecting the mechanism of its cytotoxic activity.
METHODS: Harmine and harmaline contents of the extract were determined using an HPTLC method. DNA topoisomerase I enzyme needed for investigating inhibitory effect of the compounds using DNA relaxation assay, was partially purified from the human placenta. DNA relaxation assay is based on the conversion of a supercoiled plasmid substrate to its relaxed form by the catalytic activity of the enzyme. The supercoiled substrate and its relaxed product can be easily distinguished using agarose gel electrophoresis, since the relaxed topological isomers of DNA migrate more slowly than supercoiled species.
RESULTS: Using HPTLC method, it was found that each gram of dried extract contained 55.5 and 79.0 mg of harmine and harmaline respectively. In the DNA relaxation assay, order of potency was harmine > harmane > harmaline > extract. The most active compound was harmine with IC50 value of 13.5 +/- 1.7 microg/ml.
CONCLUSIONS: Our in vitro findings demonstrate that P. harmala seeds extract do inhibit human DNA topoisomerase I and based on the results of HPTLC analysis, it appears that the biological activity of the extract can be explained by its beta-carboline content.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042115

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  29 in total

1.  Hairy root induction and plant regeneration of medicinal plant Dracocephalum kotschyi.

Authors:  Ali Sharafi; Haleh Hashemi Sohi; Pejman Azadi; Ata Allah Sharafi
Journal:  Physiol Mol Biol Plants       Date:  2014-01-26

2.  Harmaline and harmalol inhibit the carcinogen-activating enzyme CYP1A1 via transcriptional and posttranslational mechanisms.

Authors:  Mohamed A M El Gendy; Anatoly A Soshilov; Michael S Denison; Ayman O S El-Kadi
Journal:  Food Chem Toxicol       Date:  2011-10-21       Impact factor: 6.023

3.  Evaluation of the effect of Peganum harmala extracts on the in vitro viability of Leishmania tropica promastigotes in comparison to Glucantime.

Authors:  Manar Madah; Shaden Haddad; Mays Khazem
Journal:  J Parasit Dis       Date:  2020-09-27

4.  Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.

Authors:  Kunal Kumar; Peng Wang; Roberto Sanchez; Ethan A Swartz; Andrew F Stewart; Robert J DeVita
Journal:  J Med Chem       Date:  2018-08-21       Impact factor: 7.446

Review 5.  Recent trends in targeted anticancer prodrug and conjugate design.

Authors:  Yashveer Singh; Matthew Palombo; Patrick J Sinko
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

6.  Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities.

Authors:  Adil Astulla; Kazumasa Zaima; Yosuke Matsuno; Yusuke Hirasawa; Wiwied Ekasari; Aty Widyawaruyanti; Noor Cholies Zaini; Hiroshi Morita
Journal:  J Nat Med       Date:  2008-06-04       Impact factor: 2.343

7.  Benzoxazines as new human topoisomerase I inhibitors and potential poisons.

Authors:  Egemen Foto; Çigdem Özen; Fatma Zilifdar; Betül Tekiner-Gülbaş; İlkay Yıldız; Esin Akı-Yalçın; Nuran Diril; İsmail Yalçın
Journal:  Daru       Date:  2019-12-12       Impact factor: 3.117

8.  A series of beta-carboline derivatives inhibit the kinase activity of PLKs.

Authors:  Xiaomin Han; Jing Zhang; Liang Guo; Rihui Cao; Yongzhen Li; Ni Li; Qin Ma; Jialin Wu; Yanchang Wang; Shuyi Si
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

9.  Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.

Authors:  Kunal Kumar; Peng Wang; Jessica Wilson; Viktor Zlatanic; Cecilia Berrouet; Susmita Khamrui; Cody Secor; Ethan A Swartz; Michael Lazarus; Roberto Sanchez; Andrew F Stewart; Adolfo Garcia-Ocana; Robert J DeVita
Journal:  J Med Chem       Date:  2020-02-19       Impact factor: 7.446

10.  Rhythmic binding of Topoisomerase I impacts on the transcription of Bmal1 and circadian period.

Authors:  Yoshiaki Onishi; Yasuhiro Kawano
Journal:  Nucleic Acids Res       Date:  2012-08-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.